Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1H-pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study
作者： Jiachen Wen , Qun Niu , Jiang Liu , Yu Bao , Jinyu Yang
DOI: 10.1016/J.BMCL.2015.12.007
关键词: Vorinostat 、 Alkyl 、 Histone deacetylase 、 IC50 、 Methylation 、 Chemistry 、 Stereochemistry 、 Pyrazole 、 Histone deacetylase inhibitor 、 Thiol
摘要: A series of novel thiol-based histone deacetylase (HDAC) inhibitors bearing 3-phenyl-1H-pyrazole-5-carboxamide scaffold as surface recognition motif was designed, synthesized, and …
sci-hub.se 参考文章(24)
Lei Zhang, Yantao Han, Qixiao Jiang, Chunbo Wang, Xuehong Chen, Xiaoguang Li, Fuming Xu, Yuqi Jiang, Qiang Wang, Wenfang Xu, Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy. Medicinal Research Reviews. ,vol. 35, pp. 63- 84 ,(2015) , 10.1002/MED.21320
Yen-Yi Juo, Xue-Jun Gong, Ankita Mishra, Xiao Cui, Stephen B Baylin, Nilofer S Azad, Nita Ahuja, Epigenetic therapy for solid tumors: from bench science to clinical trials Epigenomics. ,vol. 7, pp. 215- 235 ,(2015) , 10.2217/EPI.14.73
Yukihiro Itoh, Takayoshi Suzuki, Akiyasu Kouketsu, Nobuaki Suzuki, Satoko Maeda, Minoru Yoshida, Hidehiko Nakagawa, Naoki Miyata, Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. Journal of Medicinal Chemistry. ,vol. 50, pp. 5425- 5438 ,(2007) , 10.1021/JM7009217
M. Ondetti, B Rubin, D. Cushman, Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents Science. ,vol. 196, pp. 441- 444 ,(1977) , 10.1126/SCIENCE.191908
Alan P. Kozikowski, Yufeng Chen, Arsen Gaysin, Bin Chen, Melissa A. D'Annibale, Carla M. Suto, Brett C. Langley, Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. Journal of Medicinal Chemistry. ,vol. 50, pp. 3054- 3061 ,(2007) , 10.1021/JM070178X
Maria New, Heidi Olzscha, Nicholas B. La Thangue, HDAC inhibitor-based therapies: Can we interpret the code? Molecular Oncology. ,vol. 6, pp. 637- 656 ,(2012) , 10.1016/J.MOLONC.2012.09.003
Alan P. Kozikowski, Yufeng Chen, Arsen M. Gaysin, Doris N. Savoy, Daniel D. Billadeau, Ki Hwan Kim, Chemistry, Biology, and QSAR Studies of Substituted Biaryl Hydroxamates and Mercaptoacetamides as HDAC Inhibitors—Nanomolar‐Potency Inhibitors of Pancreatic Cancer Cell Growth ChemMedChem. ,vol. 3, pp. 487- 501 ,(2008) , 10.1002/CMDC.200700314
Jennifer S. Carew, Francis J. Giles, Steffan T. Nawrocki, Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy Cancer Letters. ,vol. 269, pp. 7- 17 ,(2008) , 10.1016/J.CANLET.2008.03.037
Matthias G. J. Baud, Patricia Haus, Thomas Leiser, Franz-Josef Meyer-Almes, Matthew J. Fuchter, Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A. ChemMedChem. ,vol. 8, pp. 149- 156 ,(2013) , 10.1002/CMDC.201200450
Olaf Witt, Hedwig E. Deubzer, Till Milde, Ina Oehme, HDAC family: What are the cancer relevant targets? Cancer Letters. ,vol. 277, pp. 8- 21 ,(2009) , 10.1016/J.CANLET.2008.08.016